Scientists in Birmingham are running one of the first UK trials of a new drug offering hope to people suffering hereditary forms of both breast and ovarian cancer.

The Cancer Research UK clinical trial is open to patients who have already developed an advanced form of breast or ovarian cancer and have been diagnosed with faults in the known cancer susceptibility genes BRCA1 or BRCA2.

The patients on the phase II trial are receiving a potent anti-cancer drugs known as PARP inhibitors.

Dr Daniel Rea, who is running the trial at the Cancer Research UK Centre in Birmingham, said: “People who inherit faults in these genes have a 50-80 per cent chance of developing cancer.

“Currently people with hereditary forms of breast and ovarian cancer are treated in the same way as every other patient who develops advanced stage disease. We hope this trial will show that by using the PARP inhibitor we can offer them more targeted, effective treatment.”

Mutations in the BRCA1 or BRCA2 genes are responsible for around five per cent of the 45,500 cases of breast cancer diagnosed annually in the UK and for more than five percent of the 6,615 cases of ovarian cancer diagnosed each year.

If this trial is successful in the long-term, the researchers believe this treatment could offer hope for the future by paving the way for the drug to be used as a preventative treatment.

Dr Nigel Blackburn, Cancer Research UK’s director of drug development – whose team are managing the trial, said: “There is a huge amount of interest in the potential for PARP inhibitors and Cancer Research UK is proud to have pioneered research into this class of drug.”

The phase II trial is now open and is likely to take 18 months to complete. Researchers are aiming to recruit 56 patients.

For more information on how to take part visit Cancer Research UK’s patient information website www.cancerhelp.org.uk or call Cancer Research UK’s cancer information nurses on 0808 800 4040.